QURE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QURE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
uniQure NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4.30 Mil. uniQure NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $63.30 Mil. uniQure NV's annualized EBITDA for the quarter that ended in Sep. 2024 was $-99.25 Mil. uniQure NV's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.68.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for uniQure NV's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of uniQure NV was 0.39. The lowest was -1.32. And the median was -0.49.
The historical data trend for uniQure NV's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.64 | -0.56 | 0.39 | -1.32 | -0.55 |
uniQure NV Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.48 | -0.69 | -0.74 | -0.81 | -0.68 |
For the Biotechnology subindustry, uniQure NV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, uniQure NV's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where uniQure NV's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
uniQure NV's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (8.344 | + | 130.065) | / | -253.1 | |
= | -0.55 |
uniQure NV's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (4.298 | + | 63.298) | / | -99.248 | |
= | -0.68 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.
uniQure NV (NAS:QURE) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of uniQure NV's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Walid Abi-saab | officer: Chief Medical Officer | C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP |
Pierre Caloz | officer: Chief Operating Officer | UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP |
Christian Klemt | officer: Chief Financial Officer | PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP |
Madhavan Balachandran | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Rachelle Suzanne Jacques | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Robert Gut | director | C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025 |
Leonard E Post | director | |
Jeannette Potts | officer: See Remarks | C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472 |
Jack Kaye | director | C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022 |
Jeremy P. Springhorn | director | C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421 |
Paula Soteropoulos | director | 49 WINONA STREET, PEABODY MA 01960 |
David D. Meek | director | 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906 |
Matthew C Kapusta | director, officer: CEO, Managing Director | 7358 MCVAY ROAD, GERMANTOWN TN 38138 |
Ricardo Dolmetsch | officer: President, R&D | 113 HARTWELL AVENUE, LEXINGTON MA 02421 |
Kuta Alexander Edward Iii | officer: Executive VP, Operations | 239 WILLIS ROAD, SUDBURY MA 01776 |
From GuruFocus
By GuruFocus Research • 02-08-2024
By Marketwired • 08-01-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 09-23-2024
By GuruFocus Research • 02-08-2024
By GuruFocus News • 10-18-2024
By Marketwired • 07-23-2024
By GuruFocus Research • 02-28-2024
By Marketwired • 08-15-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.